Literature DB >> 3672048

Epidemiology and immunity to tetanus in Sweden.

B Christenson1, M Böttiger.   

Abstract

An investigation of tetanus antitoxin titres in the Swedish population was carried out in 1985. In Sweden, primary vaccination against tetanus has consisted of 3 doses at intervals of 4-6 weeks, beginning in the 2nd or 3rd month of life. A booster dose is offered to school children at 8-10 years of age. Three levels of antitoxin concentration (0.01, 0.05 and 0.1 U/ml) are used to demonstrate different titre levels. The interpretation is based on the premise that a serum level of 0.01 U/ml is sufficient to protect the subject against clinical tetanus. A protective titre level (greater than 0.01 U/ml) was found in 98-99% of children and young adults. A rapid decrease in the number of children with high titres (0.05-0.1 U/ml) was observed after the age of 1 and was very low in the 4-5-year-old children. An increase in the number with titres of 0.05 and 0.1 U/ml was seen after the booster dose given at school. A protective level was detected in all 21-30-year-old men and in 94% of the women, in 94% of 31-50-year-old men and in 73% of the women in the same age group. 70% of 31-40-year-old men reached antitoxin concentrations of 0.1 U/ml, and 38% of the 41-50-year-olds. The corresponding figures for women were 22% and 16% respectively. In people over 60 years, 80% of the men and 56% of the women reached protective levels of antibodies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3672048     DOI: 10.3109/00365548709021675

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  Routine tetanus immunizations for adults: once is enough.

Authors:  F M LaForce
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

2.  Diphtheria-tetanus overimmunization in children with no records: can it be prevented?

Authors:  J W Frank; R Schabas; R Arshinoff; R Brant
Journal:  CMAJ       Date:  1989-12-15       Impact factor: 8.262

3.  Tetanus incidence and immunity in Poland.

Authors:  A Galazka; B Kardymowicz
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

4.  Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.

Authors:  M Pasetti; P Eriksson; F Ferrero; M Manghi
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

5.  Anti-tetanus toxin titers in sera of the women who gave births in 1985 and 1989 in Gipuzkoa (Basque Country, Spain).

Authors:  E Perez-Trallero; G Cilla; J R Saenz-Dominguez; H Esparza; J L Díaz-de-Tuesta; M Urbieta
Journal:  Eur J Epidemiol       Date:  1995-04       Impact factor: 8.082

6.  The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV).

Authors:  P Laroche; M Barrand; S C Wood; K Van Hasbrouck; J Lang; E Harzer; L Hessel
Journal:  Infection       Date:  1999 Jan-Feb       Impact factor: 7.455

7.  Clinician awareness of tetanus-diphtheria vaccination in trauma patients: a questionnaire study.

Authors:  Young-Hoon Yoon; Sung-Woo Moon; Sung-Hyuk Choi; Young-Duck Cho; Jung-Youn Kim; Young Ho Kwak
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-05-15       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.